Cover Story
Conversation with The Cancer Letter
In an in-depth interview with The Cancer Letter, an FDA official clarified the agency's criteria for approval of drugs that target PD-1 and PD-L1.
Free
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt - Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes
- MD Anderson launches Institute for Cell Therapy Discovery & Innovation